Edition:
United States

Michael Erman

Sarepta surges after Pfizer gene therapy data raises safety concerns

Jun 28 2019

Shares of Sarepta Therapeutics Inc surged 15% on Friday after some safety concerns were raised in a small, early-stage study of a competing gene therapy for a rare muscle-wasting disorder from Pfizer Inc .

UPDATE 7-AbbVie looks beyond Humira with $63 bln deal for Botox-maker Allergan

Jun 25 2019

June 25 Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion, giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses U.S. patent protection.

Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries

Jun 20 2019

NEW YORK Merck & Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it Medicare program on lower prices in other countries would face legal challenges if adopted.

Pfizer makes $10.6 billion cancer bet in cash deal for Array Biopharma

Jun 17 2019

Pfizer Inc said on Monday it would buy Array Biopharma Inc for $10.64 billion in cash, a deal it hopes will help make it a leader in colon cancer and build up its pipeline of oncology drugs.

FDA approves Lilly's migraine drug as first ever cluster headache treatment

Jun 04 2019

NEW YORK Eli Lilly and Co's migraine treatment Emgality on Tuesday became the first drug to gain U.S. approval for decreasing the frequency of episodic cluster headache attacks, the Food and Drug Administration said https://reut.rs/2QMtzVE.

NHS England, Biogen reach deal on pricey drug for deadly disorder

May 14 2019

NEW YORK England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

NHS England, Biogen reach deal on pricey drug for deadly disorder

May 14 2019

NEW YORK England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

NHS England, Biogen reach deal on pricey drug for deadly disorder

May 14 2019

NEW YORK, May 14 England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

U.S. government to require drugmakers to show prices in TV ads

May 08 2019

The Trump administration on Wednesday said it will require drugmakers to disclose the list price of prescription drugs in direct-to-consumer television advertisements, part of the government's efforts to lower costs for U.S. consumers.

World News